tirzepatide sleep apnea fda approval Diabetes drug resolves in up to 52% of patients—is in the cards? FDA Approves Zepbound for Sleep

Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (Award-9)

The risk of upper gastrointestinal bleeding is rare with semaglutide alone, with no increased incidence in major clinical trials

In addition, in response to the semaglutide and dulaglutide shortages, the TGA is endeavouring to ensure the fair distribution of these medications in the future

Record Weight Loss Extensive Research The SURMOUNT clinical trial program demonstrated unprecedented weight loss with tirzepatide, averaging 22.5% of body weight at the highest dose (15mg weekly) in the SURMOUNT-1 trial - weight loss comparable to bariatric surgery